awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q52344613-168E60E4-4D4F-43DE-A9F9-F46C031C9F38
Q52344613-168E60E4-4D4F-43DE-A9F9-F46C031C9F38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52344613-168E60E4-4D4F-43DE-A9F9-F46C031C9F38
Current Strategies to Enhance Anti-Tumour Immunity.
P2860
Q52344613-168E60E4-4D4F-43DE-A9F9-F46C031C9F38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52344613-168E60E4-4D4F-43DE-A9F9-F46C031C9F38
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b7c788beef4e9ad60f726bd6db757eb3b1444c3a
P2860
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.